Cargando…

Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

PURPOSE: The aim of this study is to evaluate the long-term outcome of patients with locally advanced breast cancer treated with neoadjuvant systemic chemotherapy (NST) in routine clinical practice. METHODS: Four hundred and nine patients were identified between January 1999 and December 2011. All p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelucci, Domenico, Tinari, Nicola, Grassadonia, Antonino, Cianchetti, Ettore, Ausili-Cefaro, Giampiero, Iezzi, Laura, Zilli, Marinella, Grossi, Simona, Ursini, Lucia Anna, Scognamiglio, Maria Teresa, Castrilli, Graziella, De Tursi, Michele, Noccioli, Paolo, Cioffi, Pasquale, Iacobelli, Stefano, Natoli, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549406/ https://www.ncbi.nlm.nih.gov/pubmed/23052698 http://dx.doi.org/10.1007/s00432-012-1325-9

Ejemplares similares

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression
por: Peri, Marta, et al.
Publicado: (2019)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial
por: Ursini, Lucia Anna, et al.
Publicado: (2022)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
por: Belfiglio, Maurizio, et al.
Publicado: (2011)

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
por: Di Marino, Pietro, et al.
Publicado: (2022)

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Correction: Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer
por: Brocco, Davide, et al.
Publicado: (2022)

Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts
por: De Tursi, Michele, et al.
Publicado: (2017)

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
por: Fiorentino, B., et al.
Publicado: (1992)

Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.
por: Natoli, C., et al.
Publicado: (1993)

Prognostic value of a novel circulating serum 90K antigen in breast cancer.
por: Iacobelli, S., et al.
Publicado: (1994)

The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
por: Brocco, Davide, et al.
Publicado: (2020)

Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVT®) in Parkinson’s disease
por: Marchese, Maria Raffaella, et al.
Publicado: (2022)

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
por: De Lellis, Laura, et al.
Publicado: (2021)

Correction to: Oropharyngeal Dysphagia After Hospitalization for COVID-19 Disease: Our Screening Results
por: Marchese, Maria Rafaella, et al.
Publicado: (2021)

Oropharyngeal Dysphagia After Hospitalization for COVID-19 Disease: Our Screening Results
por: Marchese, Maria Raffaella, et al.
Publicado: (2021)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation
por: Brocco, D., et al.
Publicado: (2019)

Corrigendum to “Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation”
por: Brocco, D., et al.
Publicado: (2020)

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
por: Veschi, Serena, et al.
Publicado: (2018)

Exosomes as Pleiotropic Players in Pancreatic Cancer
por: De Lellis, Laura, et al.
Publicado: (2021)

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
por: Krasniqi, E., et al.
Publicado: (2021)

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors
por: Brocco, Davide, et al.
Publicado: (2021)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gvoenp6dtpj6lgc22tqaha4cq3